Please use this identifier to cite or link to this item:
標題: 表現異種異體黑色素分化抗原之DNA對於黑色素瘤小鼠的抗腫瘤免疫反應
Antitumor immune responses in melanoma-bearing mice received DNA expressing xenogeneic melanosomal differentiation antigens
作者: 徐子涵
Hsu, Tz-Han
關鍵字: 黑色素瘤小鼠
Melanoma-bearing mice
DNA vaccine
Antigen-specific immune response
Antitumor efficacy
出版社: 獸醫學系暨研究所
引用: Alexander, A.N., Huelsmeyer, M.K., Mitzey, A., Dubielzig, R.R., Kurzman, I.D., Macewen, E.G., and Vail, D.M., 2006. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer immunology, immunotherapy : CII 55, 433-442. Babiuk, S., Baca-Estrada, M.E., Foldvari, M., Middleton, D.M., Rabussay, D., Widera, G., and Babiuk, L.A., 2004. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. Journal of biotechnology 110, 1-10. Banchereau, J., and Palucka, A.K., 2005. Dendritic cells as therapeutic vaccines against cancer. Nature reviews. Immunology 5, 296-306. Barker, B.F., Carpenter, W.M., Daniels, T.E., Kahn, M.A., Leider, A.S., Lozada-Nur, F., Lynch, D.P., Melrose, R., Merrell, P., Morton, T., Peters, E., Regezi, J.A., Richards, S.D., Rick, G.M., Rohrer, M.D., Slater, L., Stewart, J.C., Tomich, C.E., Vickers, R.A., Wood, N.K., and Young, S.K., 1997. Oral mucosal melanomas: the WESTOP Banff workshop proceedings. Western Society of Teachers of Oral Pathology. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 83, 672-679. Barrow, C., Browning, J., MacGregor, D., Davis, I.D., Sturrock, S., Jungbluth, A.A., and Cebon, J., 2006. Tumor antigen expression in melanoma varies according to antigen and stage. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 764-771. Baskar, S., Glimcher, L., Nabavi, N., Jones, R.T., and Ostrand-Rosenberg, S., 1995. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. The Journal of experimental medicine 181, 619-629. Bateman, K.E., Catton, P.A., Pennock, P.W., and Kruth, S.A., 1994. Radiation therapy for the treatment of canine oral melanoma. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 8, 267-272. Bei, R., and Scardino, A., 2010. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. Journal of biomedicine & biotechnology 2010, 102758. Bergman, P.J., 2007. Canine oral melanoma. Clinical techniques in small animal practice 22, 55-60. Bergman, P.J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., Wulderk, M., Jeffers, Y., Sadelain, M., Hohenhaus, A.E., Segal, N., Gregor, P., Engelhorn, M., Riviere, I., Houghton, A.N., and Wolchok, J.D., 2003. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research 9, 1284-1290. Birchard, S., and Carothers, M., 1990. Aggressive surgery in the management of oral neoplasia. The Veterinary clinics of North America. Small animal practice 20, 1117-1140. Bitton, R.J., Guthmann, M.D., Gabri, M.R., Carnero, A.J., Alonso, D.F., Fainboim, L., and Gomez, D.E., 2002. Cancer vaccines: an update with special focus on ganglioside antigens. Oncology reports 9, 267-276. Bolon, B., Calderwood Mays, M.B., and Hall, B.J., 1990. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Veterinary pathology 27, 96-102. Boria, P.A., Murry, D.J., Bennett, P.F., Glickman, N.W., Snyder, P.W., Merkel, B.L., Schlittler, D.L., Mutsaers, A.J., Thomas, R.M., and Knapp, D.W., 2004. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224, 388-394. Bostock, D.E., 1979. Prognosis after surgical excision of canine melanomas. Veterinary pathology 16, 32-40. Carvalho, L.H., Hafalla, J.C., and Zavala, F., 2001. ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses. Journal of immunological methods 252, 207-218. Catchpole, B., Gould, S.M., Kellett-Gregory, L.M., and Dobson, J.M., 2002. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma. The Journal of small animal practice 43, 464-467. Cheng, T.Y., Wu, J.T., and Lin, R.H., 1998. Induction of tumor-specific T cell response by cognating tumor cells with foreign antigen-primed Th cells. International immunology 10, 1397-1406. Choi, C., and Kusewitt, D.F., 2003. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Veterinary pathology 40, 713-718. Cotchin, E., 1955. Melanotic tumours of dogs. Journal of comparative pathology 65, 115-129. Culp, W.D., Neal, R., Massey, R., Egevad, L., Pisa, P., and Garland, D., 2006. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. Journal of proteome research 5, 1332-1343. Danko, I., and Wolff, J.A., 1994. Direct gene transfer into muscle. Vaccine 12, 1499-1502. Das, M., Gabriely, I., and Barzilai, N., 2004. Caloric restriction, body fat and ageing in experimental models. Obesity reviews : an official journal of the International Association for the Study of Obesity 5, 13-19. Davis, H.L., Michel, M.L., and Whalen, R.G., 1993. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Human molecular genetics 2, 1847-1851. de Gruijl, T.D., van den Eertwegh, A.J., Pinedo, H.M., and Scheper, R.J., 2008. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer immunology, immunotherapy : CII 57, 1569-1577. De Las Casas, L.E., Raso, D.S., Baird, D.B., and Silverman, J.F., 1998. FNA of malignant melanoma: a brown stain without brown stains? Diagnostic Cytopathology 19, 151-152. Dorn, C.R., and Priester, W.A., 1976. Epidemiologic analysis of oral and pharyngeal cancer in dogs, cats, horses, and cattle. Journal of the American Veterinary Medical Association 169, 1202-1206. Dow, S.W., Elmslie, R.E., Willson, A.P., Roche, L., Gorman, C., and Potter, T.A., 1998. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. The Journal of clinical investigation 101, 2406-2414. Engelhorn, M.E., Guevara-Patino, J.A., Noffz, G., Hooper, A.T., Lou, O., Gold, J.S., Kappel, B.J., and Houghton, A.N., 2006. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nature medicine 12, 198-206. Feltquate, D.M., 1998. DNA vaccines: vector design, delivery, and antigen presentation. Journal of cellular biochemistry. Supplement 30-31, 304-311. Fournel-Fleury, C., Magnol, J.P., and Guelfi, J.F., 1994. Color atlas of cancer cytology of the dog and cat. Conference Nationale des Veterinaires Specialises en Petits Animaux, Paris, France 126, 83-84. Freeman, K.P., Hahn, K.A., Harris, F.D., and King, G.K., 2003. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 17, 96-101. Gabrilovich, D., 2004. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature reviews. Immunology 4, 941-952. Gilboa, E., Nair, S.K., and Lyerly, H.K., 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer immunology, immunotherapy : CII 46, 82-87. Goldberg, S.M., Bartido, S.M., Gardner, J.P., Guevara-Patino, J.A., Montgomery, S.C., Perales, M.A., Maughan, M.F., Dempsey, J., Donovan, G.P., Olson, W.C., Houghton, A.N., and Wolchok, J.D., 2005. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clinical cancer research : an official journal of the American Association for Cancer Research 11, 8114-8121. Goldschmidt, M.H., 1985. Benign and malignant melanocytic neoplasms of domestic animals. The American Journal of dermatopathology 7 Suppl, 203-212. Gridley, D.S., Miller, G.M., and Pecaut, M.J., 2007. Radiation and primary response to lipopolysaccharide: bone marrow-derived cells and susceptible organs. In vivo 21, 453-461. Grosenbaugh, D.A., Leard, A.T., Bergman, P.J., Klein, M.K., Meleo, K., Susaneck, S., Hess, P.R., Jankowski, M.K., Jones, P.D., Leibman, N.F., Johnson, M.H., Kurzman, I.D., and Wolchok, J.D., 2011. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American journal of veterinary research 72, 1631-1638. Guevara-Patino, J.A., Engelhorn, M.E., Turk, M.J., Liu, C., Duan, F., Rizzuto, G., Cohen, A.D., Merghoub, T., Wolchok, J.D., and Houghton, A.N., 2006. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. The Journal of clinical investigation 116, 1382-1390. Gyorffy, S., Rodriguez-Lecompte, J.C., Woods, J.P., Foley, R., Kruth, S., Liaw, P.C., and Gauldie, J., 2005. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 19, 56-63. Hahn, K.A., DeNicola, D.B., Richardson, R.C., and Hahn, E.A., 1994. Canine oral malignant melanoma: Prognostic utility of an alternative staging system. Journal of Small Animal Practice 35, 251-256. Harvey, H.J., MacEwen, E.G., and Braun, D., 1981. Prognostic criteria for dogs with oral melanoma. Journal of the American Veterinary Medical Association 178, 580-582. Haupt, K., Roggendorf, M., and Mann, K., 2002. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Experimental biology and medicine 227, 227-237. Hawkins, W.G., Gold, J.S., Dyall, R., Wolchok, J.D., Hoos, A., Bowne, W.B., Srinivasan, R., Houghton, A.N., and Lewis, J.J., 2000. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 128, 273-280. Henry, C.J., Brewer, W.G., Jr., Whitley, E.M., Tyler, J.W., Ogilvie, G.K., Norris, A., Fox, L.E., Morrison, W.B., Hammer, A., Vail, D.M., and Berg, J., 2005. Canine digital tumors: a veterinary cooperative oncology group retrospective study of 64 dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 19, 720-724. Hickman, D.L., and Swan, M., 2010. Use of a body condition score technique to assess health status in a rat model of polycystic kidney disease. Journal of the American Association for Laboratory Animal Science : JAALAS 49, 155-159. Hoinghaus, R., Mischke, R., and Hewicker-Trautwein, M., 2002. Use of immunocytochemical techniques in canine melanoma. Journal of veterinary medicine. A, Physiology, pathology, clinical medicine 49, 198-202. Horiuchi, Y., Tominaga, M., Ichikawa, M., Yamashita, M., Jikumaru, Y., Nariai, Y., Nakajima, Y., Kuwabara, M., and Yukawa, M., 2009. Increase of regulatory T cells in the peripheral blood of dogs with metastatic tumors. Microbiology and immunology 53, 468-474. Hsiung, Y.H., 2009. Detection of differential antigens expression in canine oral melanomas and construction of Melan-A expression plasmid. Thesis, Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H., 1998. The central role of CD4(+) T cells in the antitumor immune response. The Journal of experimental medicine 188, 2357-2368. Jager, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., and Knuth, A., 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. International journal of cancer. Journal international du cancer 66, 470-476. Jia, Z.C., Zou, L.Y., Ni, B., Wan, Y., Zhou, W., Lv, Y.B., Geng, M., and Wu, Y.Z., 2005. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta. Cancer immunology, immunotherapy : CII 54, 446-452. Jiang, S.Y., 2010. Establishment of melanoma antigen-specific cancer immunotherapy and evaluation of antitumor effect in a murine melanoma model. Thesis, Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Sakaguchi, K., Appella, E., Yannelli, J.R., Adema, G.J., Miki, T., and Rosenberg, S.A., 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the National Academy of Sciences of the United States of America 91, 6458-6462. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E., and Rosenberg, S.A., 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. Journal of immunology 154, 3961-3968. Kim, J.J., Ayyavoo, V., Bagarazzi, M.L., Chattergoon, M.A., Dang, K., Wang, B., Boyer, J.D., and Weiner, D.B., 1997. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. Journal of immunology 158, 816-826. Kim, J.J., Yang, J.S., Dang, K., Manson, K.H., and Weiner, D.B., 2001. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clinical cancer research : an official journal of the American Association for Cancer Research 7, 882s-889s. Kitchell, B.E., Brown, D.M., Luck, E.E., Woods, L.L., Orenberg, E.K., and Bloch, D.A., 1994. Intralesional implant for treatment of primary oral malignant melanoma in dogs. Journal of the American Veterinary Medical Association 204, 229-236. Kleinerman, E.S., Murray, J.L., Snyder, J.S., Cunningham, J.E., and Fidler, I.J., 1989. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer research 49, 4665-4670. Kosovsky, J.K., Matthiesen, D.T., Marretta, S.M., and Patnaik, A.K., 1991. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Veterinary surgery : VS 20, 397-401. Kutzler, M.A., and Weiner, D.B., 2008. DNA vaccines: ready for prime time? Nature reviews. Genetics 9, 776-788. Levy, A., Pitcovski, J., Frankenburg, S., Elias, O., Altuvia, Y., Margalit, H., Peretz, T., Golenser, J., and Lotem, M., 2007. A melanoma multiepitope polypeptide induces specific CD8+ T-cell response. Cellular immunology 250, 24-30. Liao, J.C., Gregor, P., Wolchok, J.D., Orlandi, F., Craft, D., Leung, C., Houghton, A.N., and Bergman, P.J., 2006. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer immunity 6, 8. Lipton, A., Harvey, H.A., Balch, C.M., Antle, C.E., Heckard, R., and Bartolucci, A.A., 1991. Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 9, 1151-1156. MacEwen, E.G., Kurzman, I.D., Vail, D.M., Dubielzig, R.R., Everlith, K., Madewell, B.R., Rodriguez, C.O., Jr., Phillips, B., Zwahlen, C.H., Obradovich, J., Rosenthal, R.C., Fox, L.E., Rosenberg, M., Henry, C., and Fidel, J., 1999. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research 5, 4249-4258. MacEwen, E.G., Patnaik, A.K., Harvey, H.J., Hayes, A.A., and Matus, R., 1986. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer investigation 4, 397-402. Manley, C.A., Leibman, N.F., Wolchok, J.D., Riviere, I.C., Bartido, S., Craft, D.M., and Bergman, P.J., 2011. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 25, 94-99. Margolin, K.A., Rayner, A.A., Hawkins, M.J., Atkins, M.B., Dutcher, J.P., Fisher, R.I., Weiss, G.R., Doroshow, J.H., Jaffe, H.S., Roper, M., and et al., 1989. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 7, 486-498. Marino, D.J., Matthiesen, D.T., Stefanacci, J.D., and Moroff, S.D., 1995. Evaluation of dogs with digit masses: 117 cases (1981-1991). Journal of the American Veterinary Medical Association 207, 726-728. Mayorga, M.E., Sanchis, D., Perez de Santos, A.M., Velasco, A., Dolcet, X., Casanova, J.M., Baradad, M., Egido, R., Pallares, J., Espurz, N., Benitez, D., Mila, J., Malvehy, J., Castel, T., Comella, J.X., Matias-Guiu, X., Vilella, R., and Marti, R.M., 2006. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma research 16, 127-135. Mendiratta, S.K., Thai, G., Eslahi, N.K., Thull, N.M., Matar, M., Bronte, V., and Pericle, F., 2001. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer research 61, 859-863. Modiano, J.F., Ritt, M.G., and Wojcieszyn, J., 1999. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of veterinary internal medicine / American College of Veterinary Internal Medicine 13, 163-174. Morgan, D.A., Ruscetti, F.W., and Gallo, R., 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007-1008. Murtaugh, M.P., and Foss, D.L., 2002. Inflammatory cytokines and antigen presenting cell activation. Veterinary immunology and immunopathology 87, 109-121. Orchard, G.E., 2000. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. The Histochemical journal 32, 475-481. Paster, E.V., Villines, K.A., and Hickman, D.L., 2009. Endpoints for mouse abdominal tumor models: refinement of current criteria. Comparative medicine 59, 234-241. Perales, M.A., Blachere, N.E., Engelhorn, M.E., Ferrone, C.R., Gold, J.S., Gregor, P.D., Noffz, G., Wolchok, J.D., and Houghton, A.N., 2002. Strategies to overcome immune ignorance and tolerance. Seminars in cancer biology 12, 63-71. Pirraco, A., Coelho, P., Rocha, A., Costa, R., Vasques, L., and Soares, R., 2010. Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells. Journal of cellular biochemistry 111, 433-441. Proulx, D.R., Ruslander, D.M., Dodge, R.K., Hauck, M.L., Williams, L.E., Horn, B., Price, G.S., and Thrall, D.E., 2003. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association 44, 352-359. Quaak, S.G., van den Berg, J.H., Toebes, M., Schumacher, T.N., Haanen, J.B., Beijnen, J.H., and Nuijen, B., 2008. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 70, 429-438. Quinn, A., Jiang, W., Velaz-Faircloth, M., Cobb, A.J., Henry, S.C., and Frothingham, R., 2002. In vivo protein expression and immune responses generated by DNA vaccines expressing mycobacterial antigens fused with a reporter protein. Vaccine 20, 3187-3192. Rakhmilevich, A.L., Imboden, M., Hao, Z., Macklin, M.D., Roberts, T., Wright, K.M., Albertini, M.R., Yang, N.S., and Sondel, P.M., 2001. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research 7, 952-961. Ramos-Vara, J.A., Beissenherz, M.E., Miller, M.A., Johnson, G.C., Pace, L.W., Fard, A., and Kottler, S.J., 2000. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Veterinary pathology 37, 597-608. Ramos-Vara, J.A., and Miller, M.A., 2011. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A. Veterinary pathology 48, 443-450. Revaz, V., Debonneville, A., Bobst, M., and Nardelli-Haefliger, D., 2008. Monitoring of vaccine-specific gamma interferon induction in genital mucosa of mice by real-time reverse transcription-PCR. Clinical and vaccine immunology : CVI 15, 757-764. Ridge, J.P., Fuchs, E.J., and Matzinger, P., 1996. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271, 1723-1726. Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Seipp, C.A., Einhorn, J.H., White, D.E., and Steinberg, S.M., 1999. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 17, 968-975. Saenger, Y.M., Li, Y., Chiou, K.C., Chan, B., Rizzuto, G., Terzulli, S.L., Merghoub, T., Houghton, A.N., and Wolchok, J.D., 2008. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer research 68, 9884-9891. Schultheiss, P.C., 2006. Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed locations of dogs. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 18, 422-425. Schwartz, R.N., Stover, L., and Dutcher, J., 2002. Managing toxicities of high-dose interleukin-2. Oncology 16, 11-20. Shackelford, C., Long, G., Wolf, J., Okerberg, C., and Herbert, R., 2002. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicologic pathology 30, 93-96. Sheu, B.C., Hsu, S.M., Ho, H.N., Lin, R.H., Torng, P.L., and Huang, S.C., 1999. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86, 1537-1543. Shirota, H., Petrenko, L., Hong, C., and Klinman, D.M., 2007. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. Journal of immunology 179, 329-336. Siegel, J.P., and Puri, R.K., 1991. Interleukin-2 toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 9, 694-704. Smedley, R.C., Lamoureux, J., Sledge, D.G., and Kiupel, M., 2011. Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms. Veterinary pathology 48, 32-40. Smith, K.A., Tam, V.L., Wong, R.M., Pagarigan, R.R., Meisenburg, B.L., Joea, D.K., Liu, X., Sanders, C., Diamond, D., Kundig, T.M., Qiu, Z., and Bot, A., 2009. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 27, 2603-2615. Smith, S.H., Goldschmidt, M.H., and McManus, P.M., 2002. A comparative review of melanocytic neoplasms. Veterinary pathology 39, 651-678. Song, K., Chang, Y., and Prud''homme, G.J., 2000a. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene therapy 7, 1527-1535. Song, K., Chang, Y., and Prud''homme, G.J., 2000b. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer. Gene therapy 7, 481-492. Spangler, W.L., and Kass, P.H., 2006. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary pathology 43, 136-149. Sparwasser, T., Hultner, L., Koch, E.S., Luz, A., Lipford, G.B., and Wagner, H., 1999. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. Journal of immunology 162, 2368-2374. Steitz, J., Bruck, J., Steinbrink, K., Enk, A., Knop, J., and Tuting, T., 2000. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. International journal of cancer. Journal international du cancer 86, 89-94. Stevenson, F.K., Ottensmeier, C.H., Johnson, P., Zhu, D., Buchan, S.L., McCann, K.J., Roddick, J.S., King, A.T., McNicholl, F., Savelyeva, N., and Rice, J., 2004. DNA vaccines to attack cancer. Proceedings of the National Academy of Sciences of the United States of America 101 Suppl 2, 14646-14652. Sulaimon, S., Kitchell, B., and Ehrhart, E., 2002. Immunohistochemical detection of melanoma-specific antigens in spontaneous canine melanoma. Journal of comparative pathology 127, 162-168. Takeda, A., Homma, S., Okamoto, T., Kufe, D., and Ohno, T., 2003. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. European journal of clinical investigation 33, 897-904. Tamura, K., Yamada, M., Isotani, M., Arai, H., Yagihara, H., Ono, K., Washizu, T., and Bonkobara, M., 2008. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. Veterinary journal 175, 126-129. Tanaka, M., Kaneda, Y., Fujii, S., Yamano, T., Hashimoto, K., Huang, S.K., and Hoon, D.S., 2002. Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. Molecular therapy : the journal of the American Society of Gene Therapy 5, 291-299. Tanaka, M., Kogawa, K., Nishihori, Y., Kuribayashi, K., Nakamura, K., Muramatsu, H., Koike, K., Sakamaki, S., and Niitsu, Y., 1997. Suppression of intracellular Cu-Zn SOD results in enhanced motility and metastasis of Meth A sarcoma cells. International journal of cancer. Journal international du cancer 73, 187-192. Tarrant, J., Stokol, T., Bartol, J., Wakshlag, J., and Blue, J., 2001. Diagnosis of malignant melanoma in a horse from cytology of body cavity fluid and blood. Equine veterinary journal 33, 531-534. Theon, A.P., Rodriguez, C., and Madewell, B.R., 1997. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. Journal of the American Veterinary Medical Association 210, 778-784. Todoroff, R.J., and Brodey, R.S., 1979. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. Journal of the American Veterinary Medical Association 175, 567-571. Tominaga, M., Horiuchi, Y., Ichikawa, M., Yamashita, M., Okano, K., Jikumaru, Y., Nariai, Y., and Kadosawa, T., 2010. Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 22, 438-441. Ulmer, J.B., Deck, R.R., Dewitt, C.M., Donnhly, J.I., and Liu, M.A., 1996. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 89, 59-67. van den Berg, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B., Storm, G., Beijnen, J.H., and Hennink, W.E., 2010. Synthetic vehicles for DNA vaccination. Journal of drug targeting 18, 1-14. Weber, L.W., Bowne, W.B., Wolchok, J.D., Srinivasan, R., Qin, J., Moroi, Y., Clynes, R., Song, P., Lewis, J.J., and Houghton, A.N., 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. The Journal of clinical investigation 102, 1258-1264. White, R.A.S., 1991. Mandibulectomy and maxillectomy in the dog: long term survival in 100 cases. Journal of Small Animal Practice 3, 69-74. Widera, G., Austin, M., Rabussay, D., Goldbeck, C., Barnett, S.W., Chen, M., Leung, L., Otten, G.R., Thudium, K., Selby, M.J., and Ulmer, J.B., 2000. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. Journal of immunology 164, 4635-4640. Williams, L.E., and Packer, R.A., 2003. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). Journal of the American Veterinary Medical Association 222, 1234-1236. Wobeser, B.K., Kidney, B.A., Powers, B.E., Withrow, S.J., Mayer, M.N., Spinato, M.T., and Allen, A.L., 2007. Diagnoses and clinical outcomes associated with surgically amputated canine digits submitted to multiple veterinary diagnostic laboratories. Veterinary pathology 44, 355-361. Wolff, J.A., Ludtke, J.J., Acsadi, G., Williams, P., and Jani, A., 1992. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Human molecular genetics 1, 363-369. Yang, S.C., Hillinger, S., Riedl, K., Zhang, L., Zhu, L., Huang, M., Atianzar, K., Kuo, B.Y., Gardner, B., Batra, R.K., Strieter, R.M., Dubinett, S.M., and Sharma, S., 2004. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 2891-2901. Zhao, K., He, W., Gao, W., Lu, H., Han, T., Li, J., Zhang, X., Zhang, B., Wang, G., Su, G., Zhao, Z., Song, D., and Gao, F., 2011. Orf virus DNA vaccines expressing ORFV 011 and ORFV 059 chimeric protein enhances immunogenicity. Virology journal 8, 562.
摘要: 黑色素瘤細胞所表現的分化抗原(例如Melan-A、tyrosinase及gp100)已證實能引起毒殺性T細胞及抗體反應。本實驗室先前架構出一種同時帶有gp100 (280V)、gp100 (210M)及tyrosinase (370D)之異種異體多抗原結合位的DNA免疫治療劑。本實驗的研究目的為評估此多抗原結合位免疫治療劑,對於B16-F10黑色素瘤小鼠的抗原特異性免疫反應及抗腫瘤效力。首先,以肌肉注射方式給予黑色素瘤小鼠10 (ME 10組)、50 (ME 50組)及250 μg (ME 250組)三種不同劑量之多抗原結合位質體DNA,一週一次,共四次。結果發現ME 50及250組有顯著的抑制腫瘤生長效果(P < 0.05)。而酵素連結免疫斑點法檢測顯示,ME 250組能有效引起周邊血液中抗原特異性CD8+ T細胞免疫反應。此外酵素連結免疫吸附法及西方墨點法分析顯示,在17隻給予多抗原結合位質體DNA中的7隻小鼠發現有抗原特異性抗體反應。而存活分析試驗中發現,ME 250組的存活時間比起對照組顯著延長(P < 0.05)。總結,本研究發現異種異體重組多抗原結合位之免疫治療劑是安全的,並具有同時引起抗原特異性之細胞及體液免疫反應的潛在效力,而此抗腫瘤免疫效力能抑制B16-F10黑色素瘤生長且延長小鼠存活率及存活時間。
Melanoma cells have been found to express differentiation antigens (e.g., Melan-A, tyrosinase and gp100) that can induce cytotoxic T-cell and antibody responses. Previously, the DNA-based immunotherapeutics with genes encoding xenogeneic multiepitope (ME) comprising of gp100 (280V), gp100 (210M) and tyrosinase (370D) was constructed in our laboratory. The goal of this study was to evaluate the antigen-specific immune responses and antitumor efficacy of the ME immunotherapeutics in the B16-F10 murine melanoma model. Melanoma-bearing mice were intramuscularly injected with ME plasmid DNA in various doses including 10 (ME 10 group), 50 (ME 50 group) and 250 μg (ME 250 group) weekly for a total of four injections. Results demonstrated that significant inhibition of tumor growth was found in the ME 50 and 250 groups (P < 0.05). Antigen-specific CD8+ T-cells in peripheral blood were detected by enzyme-linked immunospot assay in all the mice of the ME 250 group. In addition, antigen-specific antibody responses were analyzed by both enzyme-linked immunosorbent assay and Western blot assay in 7 out of 17 immunized mice. The survival times of the ME 250 group were significantly longer than that of control groups (P < 0.05). In conclusion, the findings of this study demonstrated that xenogeneic recombinant ME immunotherapeutics was safe and was potential to elicit both antigen-specific cellular and antibody immune responses. This antitumor immunity had an inhibitory ability against the B16-F10 melanoma growth to improve the survival rate and survival time of mice.
其他識別: U0005-2007201217562400
Appears in Collections:獸醫學系所



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.